Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.35 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 4/20 | 0.34 |
| ▸ | IDO1 | P14902 | 2/20 | 0.33 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.33 |
| ▸ | PRCP | P42785 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.32 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.32 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.32 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.32 |
| ▸ | BCHE | P06276 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13815519 | 1.00 | HTR2A (0.35) | HTR2ACHRNB4CHRNA3HTR2CIDO1 | |
| SCHEMBL853286 | 0.81 | CHRNB4 (0.40) | HTR2ACHRNB4CHRNA3SLC6A2SLC6A3 | |
| SCHEMBL9143636 | 0.73 | RECQL (0.42) | HTR2CCYP1A2CYP2D6HTR1ASLC6A2 | |
| SCHEMBL9144960 | 0.73 | RECQL (0.42) | HTR2CCYP1A2CYP2D6HTR1ASLC6A2 | |
| SCHEMBL28829153 | 0.69 | CHRNB4 (0.37) | CHRNB4CHRNA3HTR2CIDO1PDPK1 | |
| SCHEMBL13116589 | 0.68 | CHRNB4 (0.35) | CHRNB4CHRNA3PRCP | |
| SCHEMBL13116588 | 0.68 | TSHR (0.33) | — | |
| SCHEMBL3425103 | 0.67 | CHRNB4 (0.50) | CHRNB4CHRNA3HTR2CIDO1PDPK1 | |
| SCHEMBL6940509 | 0.67 | CHRNB4 (0.50) | CHRNB4CHRNA3HTR2CIDO1PDPK1 | |
| SCHEMBL4952572 | 0.67 | HTR2A (0.41) | HTR2ASLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2350021-B1 | BRIDGED TETRAHYDRONAPHTHALENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD (CH) | 2013-03-20 | — | — | EP | disclosed |
| US-8314253-B2 | Bridged tetrahydronaphthalene derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-11-20 | — | — | US | disclosed |
| US-20110263648-A1 | BRIDGED TETRAHYDRONAPHTHALENE DERIVATIVES | ACTELION PHARMACEUTICALS LTD. (CH) | 2011-10-27 | — | — | US | disclosed |
| US-7910732-B2 | Oxidation of metal anode; complexing metal with terephthalic acid, naphthalenedicarboxylic acid, isophthalic acid, biphenyldicarboxylic acid, p-carboxycinnamic acid, fumaric acid, and/or anthracenedicarboxylic acid and another heteroorganic compound; gas storage and separation; coordination catalysts | BASF AKTIENGESELLSCHAFT (DE) | 2011-03-22 | — | — | US | disclosed |
| US-7879221-B2 | oxidation of anode comprising metal corresponding to metal ion in reaction medium in the presence of organic compound which is optionally substituted mono, bi, or polycyclic hydrocarbon in which two ring carbons have been replaced by N,O, or S, reaction of product with di, tri, or tetracarboxylic acid | BASF SE (DE) | 2011-02-01 | — | — | US | disclosed |
| US-7820648-B2 | Pyrimidine derivatives for the treatment of abnormal cell growth | PFIZER INC (US) | 2010-10-26 | — | — | US | disclosed |
| EP-2049550-B1 | METHOD FOR PRODUCING COPPER-CONTAINING ORGANOMETALLIC FRAMEWORK MATERIAL | BASF SE (DE) | 2010-01-06 | — | — | EP | disclosed |
| US-20090306420-A1 | PROCESS FOR PREPARING COPPER-COMPRISING METAL ORGANIC FRAMEWORKS | BASF SE (DE) | 2009-12-10 | — | — | US | disclosed |
| EP-2027307-B1 | PROCESS FOR PREPARING POROUS METAL ORGANIC FRAMEWORKS | BASF SE (DE) | 2009-11-04 | — | — | EP | disclosed |
| CN-101516894-A | Method for producing copper-containing organometallic framework material | BASF AG (DE) | 2009-08-26 | — | — | CN | disclosed |
| US-20090171107-A1 | PROCESS FOR PREPARING POROUS METAL ORGANIC FRAMEWORKS | BASF SE (DE) | 2009-07-02 | — | — | US | disclosed |
| CN-101473069-A | Method for preparing porous metal organic framework material | BASF AG (DE) | 2009-07-01 | — | — | CN | disclosed |
| US-20080234303-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER INC | 2008-09-25 | — | — | US | disclosed |
| US-20080214806-A1 | Method For Producing Porous Metal-Organic Framework Materials | BASF AKTIENGESELLSCHAFT (DE) | 2008-09-04 | — | — | US | disclosed |
| EP-1888817-A2 | METHOD FOR PRODUCING POROUS METAL-ORGANIC FRAMEWORK MATERIALS | BASF AKTIENGESELLSCHAFT (DE) | 2008-02-20 | — | — | EP | disclosed |
| WO-2006125761-A2 | METHOD FOR PRODUCING POROUS METAL-ORGANIC FRAMEWORK MATERIALS | BASF AKTIENGESELLSCHAFT (DE) | 2006-11-30 | — | — | WO | disclosed |
| US-7094625-B2 | Field effect transistor and method of producing the same | CANON KABUSHIKI KAISHA (JP) | 2006-08-22 | — | — | US | disclosed |
| US-20060099732-A1 | Field effect transistor and method of producing the same | CANON KABUSHIKI KAISHA (JP) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263648-A1 | BRIDGED TETRAHYDRONAPHTHALENE DERIVATIVES | CACNA1E, CACNA1B, CACNB1 | HTR2A 1332/4885CHRNB4 215/4885CHRNA3 207/4885 |
| US-20080234303-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | CCNB1, TYMS, CCNA1 | HTR2A 2192/4885CHRNB4 4782/4885CHRNA3 3731/4885 |
| US-20090171107-A1 | PROCESS FOR PREPARING POROUS METAL ORGANIC FRAMEWORKS | OSTC, OGDH, SCO2 | HTR2A 1630/4885CHRNB4 3498/4885CHRNA3 3209/4885 |
| US-20080214806-A1 | Method For Producing Porous Metal-Organic Framework Materials | SLCO4C1, GIGYF2, SLCO2A1 | HTR2A 2340/4885CHRNB4 4141/4885CHRNA3 4164/4885 |
| US-20090306420-A1 | PROCESS FOR PREPARING COPPER-COMPRISING METAL ORGANIC FRAMEWORKS | AOC1, AOC2, AOC3 | HTR2A 4240/4885CHRNB4 4363/4885CHRNA3 3962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.